AI-enabled personalized therapeutic paradigm for youthful biology
exploratoryplatform · medium
Restore youthful biology through personalized, predictive, preventive, participatory medicine enabled by multi-omics and computational personalization.
Multi-omics classification, artificial intelligence, digital twins for baseline state estimation, trajectory prediction and counterfactual intervention simulation, plus blockchain-enabled patient-controlled data participation.
2026 Journal of Translational Medicine perspective presenting the P4 medicine architecture and preliminary metabolomic aging data from 2,072 individuals.
The perspective reports preliminary metabolomic aging data identifying nine metabolites with linear age associations and proposes a digital-twin-based computational definition of personalization.
Coma reversal senolytics and stem-cell paradigm
exploratoryresearch program · medium
Explore whether disorders of consciousness after global cerebral ischemia could be reversed by reducing neuroinflammatory senescent-cell burden and stimulating neural regeneration.
Proposed two-step therapeutic paradigm: senolytic approaches to clear senescent cells and reduce neuroinflammation, followed by stem-cell therapies plus electrophysiologic or pharmacologic stimulation.
2025 Journal of Translational Medicine article proposing the treatment paradigm.
SenoVax
preclinicaldrug program · high
Eliminate senescent cells as a senolytic immunotherapy for aging-related disease and cancer applications.
Dendritic-cell-based senolytic immunotherapy created by pulsing dendritic cells with lysate from in vitro generated syngeneic senescent fibroblasts; site also describes SenoVax as an autologous approach to eliminate senescent cells.
Reported preclinical publications in 2025 and 2026, including solid tumor reduction and combination with stem-cell-derived MSCs in murine liver injury and accelerated aging models.
In preclinical models, SenoVax reduced senescence-associated biomarkers and showed tumor regression activity; in combination with pluripotent-stem-cell-derived MSCs it outperformed either monotherapy in liver injury and accelerated aging models.
SenoVax solid tumor immunotherapy program
preclinicaldrug program · high
Reduce solid tumor growth and metastasis by vaccinating against senescent cells that promote tumor pathology and immune escape.
Senolytic dendritic-cell immunotherapy using dendritic cells pulsed with senescent fibroblast lysate; tested prophylactically and therapeutically in Lewis Lung Carcinoma and other murine tumor models, including combinations with anti-PD-L1 or anti-CTLA-4 antibodies.
2025 Journal of Translational Medicine publication reporting preclinical tumor-model results.
SenoVax induced prophylactic and therapeutic tumor regression in LLC models, reduced GL281 glioma, Pan01 pancreatic cancer, and 4T1 breast cancer growth, showed synergy with checkpoint inhibitors, and did not show significant complement activation or autoantibody induction in the reported assays.
StemCellRevivify
undiscloseddrug program · medium
Rebuild damaged organs and tissues using stem cells.
Stem-cell-based regenerative therapeutic approach; supplied site analysis describes it as rebuilding damaged organs and tissues with stem cells.
Listed by Immorta Bio as a named pipeline technology.
Synergistic senolytic-regenerative therapy
preclinicalresearch program · high
Extend healthspan and lifespan by reducing senescent-cell burden before regenerative stem-cell therapy, overcoming SASP-mediated suppression of tissue repair.
Combination treatment using SenoVax senolytic dendritic-cell immunotherapy plus syngeneic pluripotent-stem-cell-derived mesenchymal stem cells in murine CCl4 liver injury and doxorubicin-induced systemic senescence models.
2026 Journal of Translational Medicine publication reporting preclinical combination results.
Combination therapy produced synergistic benefits, including biochemical improvement of liver failure parameters, reversal of accelerated-aging features, and restoration of regenerative signaling pathways; monotherapies were less effective.
